Neurosense's Drug Candidate Shows Early Signals Of Benefit In Alzheimer's Patient-Derived Neurons
Sept 10 (Reuters) - Neurosense Therapeutics Ltd NRSN.O:
NEUROSENSE'S DRUG CANDIDATE SHOWS EARLY SIGNALS OF BENEFIT IN ALZHEIMER'S PATIENT-DERIVED NEURONS
NEUROSENSE THERAPEUTICS- INITIAL PHASE 2 ROAD TRIAL RESULTS DEMONSTRATE IMPROVEMENTS IN BRAIN-CELL CONNECTIVITY HEALTH, WITH FAVORABLE SAFETY PROFILE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

Azure Growth 40%, AI Revenue 37 Billion: Why Did Microsoft Shares Fall Instead of Rise?

Nvidia Stock Prediction: Can NVDA Hit $1,000 by 2030?

Robinhood Slumps 8% After Earnings. Revenue and Profit Both Miss, Market Fears Coinbase May Follow Suit.

GOOGL Vs. MSFT: 2 Monster Stocks to Hold for the Next 5 Years

Tradingkey








